Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04, reports.
Brainstorm Cell Therapeutics Trading Up 1.1%
Shares of Brainstorm Cell Therapeutics stock traded up $0.01 on Tuesday, hitting $0.96. 60,223 shares of the company traded hands, compared to its average volume of 19,801. The firm’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $0.86. The company has a market cap of $14.22 million, a P/E ratio of -0.29 and a beta of 0.35. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69.
Brainstorm Cell Therapeutics Company Profile
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
